Life threatening liver disease during treatment with monoclonal antibodies.
Kaiser
Thorsten
T
Medizinische Klinik und Poliklinik II, Universität Leipzig, 04103 Leipzig, Germany.
Moessner
Joachim
J
Patel
Keyur
K
McHutchison
John G
JG
Tillmann
Hans L
HL
D000068879:Adalimumab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001778:Blood Coagulation Disorders / Q000139:chemically induced; D056487:Chemical and Drug Induced Liver Injury, Chronic / Q000209:etiology*; D016638:Critical Illness / Q000628:therapy*; D019694:Hepatitis B, Chronic / Q000209:etiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007565:Jaundice / Q000139:chemically induced; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*; D012008:Recurrence
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000068879:Adalimumab; C472181:efalizumab